Alpharma Eyeing Commercial, Legal Options For Gabapentin Following ANDA Stay

The company could seek a settlement with Apotex to dismiss its challenge to Alpharma’s 180-day generic marketing exclusivity for Neurontin, the lifting of the federal appeals court stay of approval or an accelerated hearing date.